Personalized Heart Failure Management: Bridging Technology and Care.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. HLM Staging and Treatment Benefit of SGLT2i Across Heart Failure Severity.Journal of cardiovascular development and disease · 2026
   Article
2. Diuretic Intensity Score and Mortality in Hospitalized Heart Failure Patients: A Multicenter Propensity-Matched Analysis.Clinical cardiology · 2026
   Article
3. Impact and safety of remote monitoring of heart failure patients managed with the HeartLogic algorithm: the HeartLogic France Cohort Study.European heart journal. Digital health · 2026
   Article
4. Diuretic Use in Heart Failure.Reviews in cardiovascular medicine · 2025
   Review
5. The Rise of Personalized Medicine in Heart Failure Management: A Narrative Review.Cureus · 2025
   Review

Corrections and comments

• Comment on
  Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE-HF.2024

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as